⁠Investing visuals
Crowdstrike $CRWD Q3 earning:

• Sales $1.01B vs Est. $983M
• EPS $0.93 vs Est. $0.81

Updated one-pager will be out tomorrow 👌

Crowdstrike $CRWD is reporting Q3'24 earnings Tuesday after hours. Here's the pre-earnings overview:

Earnings 📜
🔹Est. Revenue: 983 Mln (+25.1%)
🔹Est. EPS: $0.81 (-1.4%)

Key metrics to watch 🔎
🔸 Module adoption
🔸 Annual recurring revenue
🔸 Net retention rate - Investing visuals
tweet

⁠Quiver Quantitative
RT @InsiderRadar: $AGFY skyrocked 37% today, amazing timing by this CEO https://t.co/oMKYCJirRb

🚨BREAKING: New CEO Insider Purchase

The interim CEO of $AGFY has reported the purchase of ~$267K of the company's stock, increasing his ownership stake by 60%. - Insider Radar
tweet

⁠Quiver Quantitative
RT @InsiderRadar: $NGNE is up 20% on the day after these insider buys https://t.co/cipIradqsZ

🚨BREAKING: New Insider Purchases

The CEO and CFO of $NGNE have both reported large insider buys ($969K and $490K respectively).

This is the first insider purchase we have ever seen either of these execs report. - Insider Radar
tweet

⁠App Economy Insights
$CRWD CrowdStrike Q3 FY25:

📊 ARR +27% Y/Y to $4.02B.
📈 Net new ARR $153M (-31% Y/Y).
• Revenue +29% to $1.01B ($27M beat).
• Non-GAAP EPS $0.93 ($0.12 beat).
• FY25 revenue ~$3.93B (~$30M raise). https://t.co/3a5maezlCX
tweet

⁠Quiver Quantitative
RT @InsiderRadar: 🚨BREAKING: New CEO Insider Purchase

The CEO of $IIIV has reported the purchase of ~$2.1M of the company's stock, increasing his ownership stake by 39%.

This is the first insider purchase we have seen at the company in over a year.
tweet

⁠Capital Employed
Microcap fraudsters - oh dear. Lots of interesting responses on this short thesis.

NEW SHORT: ASP Isotopes $ASPI

ASPI has all the makings of the next nuclear meltdown.
-Failed Tech from 20 years ago
-Infamous “Microcap Fraudsters” Honig & Stetson involved
-Paid Stock Promotion
-Some South African Subsidiaries Suspiciously Missing

We are Short $ASPI https://t.co/ypn55Qu4hn - FuzzyPanda 🇺🇦
tweet

⁠Stock Analysis Compilation
Artemis on Sandoz $SDZ SW

Thesis: Sandoz is primed for growth with its biosimilar portfolio, capitalizing on expiring biologic exclusivity and commanding premium pricing in a low-competition market

(Extract from their Q3 letter) https://t.co/ep7NkIHaB8
tweet

⁠Hidden Value Gems
LVMH is down 19% YTD, still not too cheap, close to 20x fwd PE, but reasonable assuming luxury recovery, high ROIC/margins and its moat.

At what level would you buy it without any further thinking?

$MC.PA #LVMH
- I already own it
- Buying it now
- Not my type of business
- Under €500
tweet

⁠Hidden Value Gems
Anyone looked at $REAL ?

Seems like the rich are more cautious with their money too.

Still a loss-making business, but sales growing faster than at the luxury peers and the company is approaching breakeven. https://t.co/DYR80yp1Kv
tweet

⁠Stock Analysis Compilation
Artisan on Novonesis $NSISB DC

Thesis: Novonesis transforms industries with sustainable biosolutions, leveraging innovation and cost synergies for long-term growth

(Extract from their Q3 letter) https://t.co/piEkI0USos
tweet